Drug Profile
Research programme: antibody therapeutics - Adimab/Kite Pharma
Alternative Names: CAR-T therapeutics - Adimab/KiteLatest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Adimab; Kite Pharma
- Class Antibodies
- Mechanism of Action Immunostimulants; T-cell receptor antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified